Article Results:
[Sep 01, 2012] Teva Pharma, by Mark Robertson
TEVA is a global pharmaceutical that delivers both generic and proprietary drugs.
[Oct 01, 2013] Teva Pharma, by Mark Robertson
TEVA is the largest generic drug manufacturing company in the world, and is focusing on building a stronger generic drug portfolio.
[May 01, 2011] Teva Pharmaceutical, by Mark Robertson
TEVA is among the top 15 pharmaceutical companies and among the largest generic pharmaceutical companies in the world.
[Jul 01, 2010] Manifest Top 40, by Mark Robertson
Twenty seven out of thirty nine active entries have outperformed the market since selection for an accuracy rating of 69.2%, down slightly from 72.5% in March 2010.
[Jun 01, 2011] Sweet Sixteen, by Mark Robertson
The screening results this month represent our more traditional approach, seeking the highest ranked MANIFEST stocks.
[Feb 01, 2012] Group Groundhog, by Mark Robertson
This year, it’s all about the groups known as investment clubs. The group entries from clubs won the overall championship and locked down four of the top five positions.
[Dec 01, 2009] Hoard vs. Herds, by Mark Robertson
Accumulate DJ US Medical Devices.
[Oct 01, 2011] Our Collective Report Card, by Mark Robertson
Our MANIFEST 40 just celebrated its sixth birthday. This quarterly review of the most widely-followed stocks by our community is a trove of information about companies attracting the attention of thousands of like-minded investors.
[Jan 01, 2007] Sweet 16, by Mark Robertson
The highest rated companies are Oracle, Fastenal, Maxim Integrated Products and Wellpoint Health.
[May 01, 2007] Sweet 16, by Mark Robertson
The highest-rated companies are Staples, Best Buy and Oracle.
[Jun 01, 2007] Sweet 16, by Mark Robertson
The highest-rated companies are Varian Medical, Select Comfort, Staples and Walgreen.
[Jun 01, 2008] Sweet 16, by Mark Robertson
The highest-rated companies are Urban Outfitters, Starbucks and Lowe's .
[Mar 01, 2005] American Century Ultra, by Mark Robertson
A highly-respected mutual fund family with solid management characteristics and long-term results for shareholders..
[Oct 01, 2009] Manifest Top 40, by Mark Robertson
The three top performers in the MANIFEST TOP 40 with the largest annualized relative returns since inception are Quality Systems, Infosys Tech and FactSet Research.
[Dec 17, 2007] Christmas Countdown: StockWatch Reports, by Mark Robertson
With the release of the latest MANIFEST 40, we've decided to perform a bunch of StockWatch reports on the most widely-held residents in subscriber dashboards.
[Jul 01, 2009] Manifest Top 40, by Mark Robertson
The MANIFEST TOP 40 is now 3.75 years old. The list represents the most widely-followed companies from subscriber dashboards. The annualized rate of return for the stocks on your collective dashboards is (-3.0%) versus (-8.0%) for the Wilshire 5000.
[Dec 17, 2008] Manifest Top 40, by Mark Robertson
The outlook continues to be favorable for the MANIFEST 40. It's the relative return that matters with a long-term perspective. We'll take +6% and wish everybody the best of the holiday season.
[Apr 10, 2013] Sweet 16, by Mark Robertson
Panning For High-Quality Stocks On Sale
[Jul 25, 2018] MANIFEST 40 Update, by Mark Robertson
Our MANIFEST 40 is a celebration of collective excellence in stock selection, strategy and disciplined patience. The rate of return since inception (2005) is 10.1%.
[Sep 03, 2020] MANIFEST 40 Update, by Mark Robertson
As we approach the 15th birthday of the Manifest Investing 40 most widely-followed stocks, we welcome Amazon (AMZN) and Disney (DIS) to the party.
[Oct 01, 2013] Sweet 16, by Mark Robertson
Every week we sort through the update batch and feature companies with solid return forecasts according to Value Line. This month, we share the results of that screen.
[Jan 01, 2010] Sweet '16': Resounding Resolutions, by Mark Robertson
With MIPAR back in single digits, shopping among the highest quality companies with the best expectations seems particularly prudent.
[Aug 01, 2010] Sweet 16, by Mark Robertson
It's pretty tough to ignore all of the healthcare stocks that keep bubbling to the tops of our screening efforts.
[May 01, 2008] Sweet 16, by Mark Robertson
The highest-rated companies are Walgreen, ENSCO and Chicago Bridge.
[Jan 01, 2007] Summing Our Financial Strength, by Mark Robertson
A company can't be best-of-breed without a high relative financial strength.
[Oct 01, 2013] Is Buy-and-Hold Dead?, by Mark Robertson
You don’t have to google very long to come up with a long list of articles and commentaries about the death of “buy and hold” as a strategy.
[Apr 07, 2006] Manifest Top 40, by Mark Robertson
Manifest consensus-by-dashboard continues to perform fairly well, delivering a 13.9% rate of return but now trails the Wilshire 5000.
[Jul 01, 2006] Manifest Top 40, by Mark Robertson
In the realm of long-term investing, patience is a virtue.
[Oct 01, 2005] Peak Interest In Quality Leaders, by Mark Robertson
In this issue, we introduce the MANIFEST 40, consisting of the stocks which appear most frequently on your collective dashboards.
[Dec 30, 2005] Manifest Top 40, by Mark Robertson
A list of the most widely-followed companies from subscriber dashboards.
[Sep 21, 2006] Manifest Top 40, by Mark Robertson
Stability within the Top 40 seems to be increasing as Home Depot continues to hold down the top position, despite some angst and shareholder discomfort.
[Dec 30, 2006] Manifest Top 40, by Mark Robertson
Our quarterly "consensus" returns with our sixth edition of the Manifest Top 40, a list of the most widely-followed stocks by subscribers.
[Mar 29, 2007] Manifest Top 40, by Mark Robertson
Our quarterly "consensus" returns with our seventh edition of the Manifest Top 40, a list of the most widely-followed stocks by subscribers.
[Dec 15, 2009] Manifest Top 40, by Mark Robertson
The three top performers in the MANIFEST TOP 40 are Cognizant Technology, Quality Systems and Infosys Tech.
[Mar 27, 2008] Manifest Top 40, by Mark Robertson
This is our 11th edition of the MANIFEST 40, covering the last 33 months. It's a list of the most widely-followed stocks by subscribers.
[Jul 01, 2007] Manifest Top 40, by Mark Robertson
Our quarterly "consensus" returns with our eighth edition of the Manifest Top 40, a list of the most widely-followed stocks by subscribers.
[May 08, 2009] Manifest Top 40, by Mark Robertson
Walgreen (WAG) continues in the lead as the company found on the highest number of subscriber dashboards. The top ten was unchanged since the December edition of the MANIFEST 40.
[Jul 01, 2008] Manifest Top 40, by Mark Robertson
This is our 12th edition of the MANIFEST 40, covering the last 3 years. It's a list of the most widely-followed stocks by subscribers.
[Sep 30, 2008] Manifest Top 40, by Mark Robertson
Our MANIFEST 40 is a list of the most widely-followed stocks by subscribers. The annualized rate of return for the stocks on our collective dashboards is 4.1% versus (0.4%) for the Wilshire 5000 since inception.
[Apr 01, 2015] MANIFEST 40 Update, by Mark Robertson
Our MANIFEST 40 is a celebration of collective excellence in stock selection, strategy and disciplined patience. We continuously monitor the 40 most-widely followed stocks by our community of subscribers at Manifest Investing.
[Aug 01, 2011] Sweet Sixteen, by Mark Robertson
This month we take a departure from our more traditional approach, as we reinforce our findings regarding the Value Line low total return forecast.
[Jan 01, 2015] Manifest Top 40 Update, by Mark Robertson
Our MANIFEST 40 is a celebration of collective excellence in stock selection, strategy and disciplined patience. We continuously monitor the 40 most-widely followed stocks by our community of subscribers at Manifest Investing.
[Apr 01, 2016] Allergan, by Mark Robertson
AGN is a well-positioned industry leader as a stand-alone company.
[Sep 01, 2010] Tin Cup Model Portfolio, by Mark Robertson
Sell Goldman Sachs, Buy Cisco and Deckers.
[Dec 21, 2005] Dashing Thru the Dashboards, by Mark Robertson
Some Perspective and Results Update.
[May 01, 2011] Welcome To The Sand Box!, by Mark Robertson
This month we celebrate the enhancements to the Manifest Investing web site.
Forum Post Results:
Teva Pharma (TEVA)
· by
Mark Robertson
·
12/18/2009 10:26 AM
·
Stocks
Teva Pharmaceutical (TEVA) is also no stranger to our community of investors. TEVA now ranks #16 on the MANIFEST 40 … meaning that a number of you...
Teva Pharma (TEVA)
· by
Mark Robertson
·
12/18/2009 10:40 AM
·
Stocks
Sales Growth Forecast We’re emphasizing 2009-2010 as the basis for a 15% sales growth projection. TEVA acquired Barr Labs during 2008 and the...
Teva Pharma (TEVA)
· by
Mark Robertson
·
12/18/2009 10:49 AM
·
Stocks
Profitability Analysis Who says there’s “no money” in generics? :) As the attached image shows, % net margin has been pretty healthy at TEVA for...
Teva Pharma (TEVA)
· by
Mark Robertson
·
12/18/2009 11:02 AM
·
Stocks
Projected Average P/E Based on their fair value estimates, both Morningstar and Speg a “reasonable” P/E for TEVA at approximately 15. For 2008, the...
Teva Pharma (TEVA)
· by
Mark Robertson
·
12/18/2009 11:03 AM
·
Stocks
Chronicle
Teva Pharma (TEVA)
· by
Mark Robertson
·
12/18/2009 11:52 AM
·
Stocks
Lurker Correspondence: What about TEVA’s long-term debt? I’ve been taught to avoid companies with debt levels like this. We love the lurkers. :)...
Teva Pharma (TEVA)
· by
Eleanor Shaltis
·
01/14/2010 03:29 PM
·
Stocks
Can someone please tell me why on the SSG for the last year or so and quarters the earnings of Teva are flat when all else is growing very well....
Teva Pharma (TEVA)
· by
Etana Finkler
·
02/07/2010 02:15 PM
·
Stocks
I’d like to know too.
Teva Pharma (TEVA)
· by
Dan Hess
·
02/07/2010 04:54 PM
·
Stocks
Eleanor I assume you are using IClub data that shows in 2008 sales were up 17.8% while EPS was down 67%. If that is your consern I suggest reading...
Teva Pharma (TEVA)
· by
Leroy Brunner
·
02/08/2010 01:42 AM
·
Stocks
TEVA’s earnings seem to be dependent on your source of data. The 05/06/07/08 earnings for TEVA from four sources are listed. AOL...
Teva Pharma (TEVA)
· by
Leroy Brunner
·
01/30/2010 12:28 AM
·
Stocks
I am curious to learn how TEVA can go from a PAR of 14.9 to a PAR of 11.4 in less than 24 hours with no apparent changes in fundamentals.
Teva Pharma (TEVA)
· by
Mark Robertson
·
01/30/2010 07:19 AM
·
Stocks
Thanks for the question, Leroy. The changes require a little digging. TEVA was part of the batch update uploaded yesterday. You’re right the sales...
Teva Pharma (TEVA)
· by
Jim Thomas
·
01/31/2010 01:14 AM
·
Stocks
Here are PAR sentitivity charts for TEVA. The chart in the lower right corner shows how forecast PE changing from 14 to 16 can move PAR from 11.9%...
Teva Pharma (TEVA)
· by
Mark Robertson
·
02/16/2010 08:22 AM
·
Stocks
Teva Pharma (TEVA) missed EPS estimates by a penny this morning, announcing before the market opens. Duck. :) Mark Robertson
Teva Pharma (TEVA)
· by
Mark Robertson
·
10/05/2016 07:17 PM
·
Stocks
This daily update lists the tickers of the stocks that became 5-star investments, according to Morningstar, as of the last market close. A stock...
Teva Pharma (TEVA)
· by
Mark Robertson
·
12/01/2016 01:56 PM
·
Stocks
Teva Pharma (TEVA) landed at the top of this week’s Fave Five. It appears that the (2016) Actavis integration is causing considerable rhino...
Teva Pharma (TEVA)
· by
Mark Robertson
·
01/05/2017 05:47 PM
·
Stocks
Teva Pharma (TEVA) will host a conference call tomorrow, January 6, at 8:00 am ET to update investors on its outlook for 2017.
Teva Pharma (TEVA)
· by
Rebecca Osborne
·
01/06/2017 09:41 PM
·
Stocks
Here’s a link to the replay of the conference call. The slides referred to in the call are on their web site. Teva Pharmaceutical Industries...
Teva Pharma (TEVA)
· by
Mark Robertson
·
01/17/2017 08:30 AM
·
Stocks
http://seekingalpha.com/article/4037221-teva-revises-outlook Summary Teva lowered its guidance for 2017, sending shares towards yearly lows....
Teva Pharma (TEVA)
· by
Mark Robertson
·
02/15/2018 09:05 AM
·
Stocks
The sole addition to Berkshire’s closely watched stock portfolio during the fourth quarter was beaten-down pharmaceutical stock Teva...
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/19/2011 07:58 AM
·
Stocks
Thanks for the questions/debate, Dan. 1) The 2014-16 average PE provided by VL seems to be heavily based upon higher PE ratios from 2000 to 2005...
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/19/2011 07:59 AM
·
Stocks
Recognizing the impact of the Great Recession, a forecast “north” of 15x seems an even higher probability if TEVA continues to execute well.
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/19/2011 08:07 AM
·
Stocks
3)TEVA has long been an active acquirer as well as an active generic drug provider. It would seem to me the increase in generic drug business would...
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/19/2011 08:21 AM
·
Stocks
4) On the technicals I note TEVA is in a general downtrend falling below many EMAs as well as the daily 13/34 EMA crossing. While the market in...
Teva Pharma (TEVA)
· by
Saul Seinberg
·
06/19/2011 05:35 PM
·
Stocks
I tried to post a note on TEVA this morning that would have embedded two charts without success. I’ll have to take remedial posting again. I have...
Teva Pharma (TEVA)
· by
Dan Hess
·
06/19/2011 09:57 PM
·
Stocks
I attribute the decline in the stock price of TEVA largely due to the potenial impact of a competitive drug by Mylan upon Copaxone. TEVA is...
Teva Pharma (TEVA)
· by
Saul Seinberg
·
06/20/2011 06:06 AM
·
Stocks
Dan, TEVA spends a lot of time in court. An important aspect of their business plan is to try and invalidate patents applicable to proprietary...
Teva Pharma (TEVA)
· by
Dan Hess
·
06/20/2011 11:10 AM
·
Stocks
Saul Thanks for the insight. I agree TEVA has been rather successful in obtaining early generic rights and I am of the view they have a very...
Teva Pharma (TEVA)
· by
Chuck Burford
·
05/22/2011 09:28 AM
·
Stocks
Has anyone else heard that BRKB is buying shares of Teva? Thanks
Teva Pharma (TEVA)
· by
Anne Manning
·
05/22/2011 01:28 PM
·
Stocks
Who is BRKB? I just bought TEVA and would be interested in this. Anne
Teva Pharma (TEVA)
· by
Ted Brooks
·
05/22/2011 01:35 PM
·
Stocks
Berkshire Hathaway B shares?
Teva Pharma (TEVA)
· by
Dan Hess
·
05/22/2011 01:36 PM
·
Stocks
BRK-B or BRK.B are the lower priced (1/30 of full shares if I recall correctly) shares of Berkshire Hathaway. i.e. Warren Buffet’s company. Dan
Teva Pharma (TEVA)
· by
Chuck Burford
·
05/22/2011 06:38 PM
·
Stocks
They are the non-voting shares of Berkshire.
Teva Pharma (TEVA)
· by
Bruce Buxton
·
05/27/2011 04:58 PM
·
Stocks
It Seem if Warren buy a stock it is done for.. I will pitch my stuff if that is true.
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/18/2011 09:10 AM
·
Stocks
An audit of probable Challenge Club nominee Teva Pharma (TEVA) … as it appeared on the Deep Value screen for June and is in the sweet spot among...
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/18/2011 09:16 AM
·
Stocks
1. Sales Growth Forecast Forget much of the history of this serial acquirer (certainly anything pre-Barr Labs) during your study. Focus on the “...
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/18/2011 09:21 AM
·
Stocks
2. Profitability Analysis Value Line has a 3-5 year forecast of 23.6% for net margin. That reconciles fairly well with both (1) the trend as shown...
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/18/2011 09:25 AM
·
Stocks
3. Projected Average P/E Value Line has a long-term forecast of 18. Based on the consensus (Morningstar has a fair value of $63 = 13x and S&P...
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/18/2011 09:29 AM
·
Stocks
Equity Analysis Guide
Teva Pharma (TEVA)
· by
Mark Robertson
·
06/18/2011 09:37 AM
·
Stocks
Technical Analysis Perhaps something of a “clincher” … TEVA appears to be near short-term support levels and is a lot closer to a relative strength...
Teva Pharma (TEVA)
· by
Dan Hess
·
06/18/2011 10:57 AM
·
Stocks
Let me play the devils advocate and ask a few questions. (bg) 1) The 2014-16 average PE provided by VL seems to be heavily based upon higher PE...
Teva Pharma (TEVA)
· by
Mark R. Johnson
·
08/24/2011 05:15 PM
·
Stocks
As of 8/24 it barely seems to have happened. Here is a cut-and-paste from Yahoo Finance: EPS_Trends Curr_Yr Next_Yr Current Est 5.06 5.63 7 Days...
Teva Pharma (TEVA)
· by
Mark Robertson
·
08/25/2011 08:22 AM
·
Stocks
Thanks, Mark. We’ve been kicking the 24/7 news cycle to the curb lately and this is a perfect demonstration of how little attention should be paid...
Teva Pharma (TEVA)
· by
Thief River Falls
·
04/04/2011 02:24 PM
·
Stocks
my group has been considering buying TEVA pharmaceutical what are your suggestions?
Teva Pharma (TEVA)
· by
Laura Scott
·
04/29/2011 09:39 AM
·
Stocks
I just purchased some for myself. After owning it years ago and making a profit, I decided to get back in based on the recent pullback in price and...
Teva Pharma (TEVA)
· by
Mark Robertson
·
05/01/2011 10:37 AM
·
Stocks
Lynn, GREAT to see you this weekend. You probably already know about this, but Cy Lynch covered Teva Pharma (TEVA) during the April Round Table....
Teva Pharma (TEVA)
· by
Mark Robertson
·
05/02/2011 03:35 PM
·
Stocks
Teva (TEVA) has agreed to acquire the outstanding shares of Cephalon (CEPH) for $81.50 a share in cash, giving the latter a total enterprise value...
Teva Pharma (TEVA)
· by
Mark Robertson
·
07/27/2011 12:17 PM
·
Stocks
Teva’s (TEVA) Q2 EPS excluding items rose to $1.10 from $1.08 a share a year earlier and beat expectations as revenue increased 11% to $4.21B. The...
Teva Pharma (TEVA)
· by
Laura Scott
·
08/02/2011 07:23 AM
·
Stocks
Teva Pharmaceutical shares slide on news that its promising oral MS drug failed its second late-stage clinical trial. The drug had been effective...
Teva Pharma (TEVA)
· by
Mark Robertson
·
08/03/2011 10:42 AM
·
Stocks
Thanks, Laura. Somebody make a note to carefully monitor for reductions in the TEVA rhino forecasts for 2011 and 2012 … and let us all know if it...